Extended-Spectrum Beta-Lactamase-Producing Pathogens in Postbiliary Surgical Infections: Resistance and Treatment Outcomes

Authors

  • Fontaine C Department of Clinical Microbiology, Sorbonne University, Paris, France Author
  • Johansson G Department of Pharmacology, Karolinska Institute, Stockholm, Sweden Author
  • Koskela E Department of Hepatobiliary Surgery, University of Turku, Turku, Finland Author

DOI:

https://doi.org/10.5281/zenodo.22664496

Keywords:

extended-spectrum beta-lactamase, biliary tract infection, hepatobiliary surgery, antimicrobial resistance, antimicrobial stewardship

Abstract

Background: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae have become
common isolates in postoperative infections following biliary and hepatobiliary surgery, driven by frequent preoperative biliary
instrumentation, recurrent hospitalization, and prior antibiotic exposure in this patient population. Objective: This case-based
review synthesizes case series and comparative cohort evidence on ESBL resistance mechanisms and prevalence, risk factors
specific to the postbiliary surgical setting, and treatment outcomes with carbapenem versus beta-lactam/beta-lactamase inhibitor
regimens, with attention to antimicrobial stewardship implications. Methods: Case reports, case series, and comparative cohort
studies addressing ESBL-producing Enterobacteriaceae in biliary tract infection, hepatobiliary and pancreatic surgery, and
endoscopic retrograde cholangiopancreatography were identified through structured searches of PubMed/MEDLINE, Europe PMC,
and journal databases; each source was individually verified against its publisher or bibliographic record before inclusion. Findings:
ESBL prevalence among biliary and postbiliary surgical Enterobacteriaceae isolates ranges from roughly one-quarter to just under
half across reported cohorts, with prior biliary drainage, recent antibiotic exposure, recurrent hospitalization, and endoscopic
instrumentation emerging as the most consistent risk factors. Comparative treatment data show that while the MERINO trial
found carbapenem therapy superior to piperacillin-tazobactam for ESBL bacteremia, several more recent retrospective and
propensity-matched studies report comparable 30-day mortality between the two regimens, particularly where OXA-1
co-production is uncommon and source control is adequate. Conclusions: Empiric broad-spectrum coverage remains reasonable at
the time of clinical deterioration in this high-risk surgical population, but the more consequential and frequently neglected
stewardship task is reliable de-escalation once culture and susceptibility data return.

References

Husna A, Rahman MM, Badruzzaman ATM, Sikder MH, Islam MR, Rahman MT, Alam J, Ashour HM (2023) Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities. Biomedicines, 11(11):2937, DOI:10.3390/biomedicines11112937.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI (2013) Clinical Impact of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Patients with Biliary Tract Infection. Digestive Diseases and Sciences, 58(3):841-849, DOI:10.1007/s10620-012-2398-7.

Li L, Zhu C, Huang H (2019) Clinical epidemiology and outcomes of biliary tract infections caused by Klebsiella pneumoniae. Annals of Translational Medicine, 7(14):304, DOI:10.21037/atm.2019.06.03.

Chen H, Han QF, Wu F (2026) Distribution of pathogenic bacteria and analysis of risk factors for surgical site infections after hepatobiliary surgery. BMC Infectious Diseases, 26(1):276, DOI:10.1186/s12879-025-12360-w.

Alipour S, Harzandi N, Sadeghi A, Rabbani A, Houri H (2024) A worrisome prevalence of extended-spectrum β-lactamase producers in patients with biliary obstruction and cholangitis: phenotypic and molecular characterization of biliary Escherichia coli and Klebsiella pneumoniae isolates. Microbial Pathogenesis, 197:107026, DOI:10.1016/j.micpath.2024.107026.

Ramírez-Giraldo C, Rodriguez Barbosa C, Isaza-Restrepo A, Avendaño-Morales V, Rojas-López S, Van-Londoño I (2024) Predictive factors associated with bile culture positivity and phenotypical antibiogram resistance patterns in patients taken to laparoscopic cholecystectomy (BACILO): protocol for a prospective observational cohort study and development of a prognostic prediction model. BMJ Open, 14(10):e086655, DOI:10.1136/bmjopen-2024-086655.

Vance MK, Cretella DA, Ward LM, Vijayvargiya P, Esquer Garrigos Z, Wingler MJB (2023) Risk Factors for Bloodstream Infections Due to ESBL-Producing Escherichia coli, Klebsiella spp., and Proteus mirabilis. Pharmacy, 11(2):74, DOI:10.3390/pharmacy11020074.

Abera D, Alemu A, Mihret A, Negash AA, Abegaz WE, Cadwell K (2023) Colonization with extended spectrum beta-lactamase and carbapenemases producing Enterobacteriaceae among hospitalized patients at the global level: a systematic review and meta-analysis. PLOS ONE, 18(11):e0293528, DOI:10.1371/journal.pone.0293528.

Nadeem MA, Awan AR, Rao AG, Ayyazuddin M, Banatwala USS, Laique S, Bansal P, Junna S, Siddiki H, Koval C, et al (2025) Role of antibiotic prophylaxis in liver transplant patients undergoing endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis. eClinicalMedicine, 89:103560, DOI:10.1016/j.eclinm.2025.103560.

Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Paterson DL, et al (2018) Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA, 320(10):984-994, DOI:10.1001/jama.2018.12163.

Månsson TS, Askemyr A, Sunnerhagen T, Tham J, Riesbeck K, Mellhammar L (2025) Piperacillin/tazobactam versus carbapenems for 30-day mortality in patients with ESBL-producing Enterobacterales bloodstream infections: a retrospective, multicenter, non-inferiority, cohort study. Infection, 53(5):1769-1777, DOI:10.1007/s15010-025-02496-x.

Hoashi K, Hayama B, Suzuki M, Sakurai A, Takehana K, Enokida T, Takeda K, Ohkushi D, Doi Y, Harada S (2022) Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis. Microbiology Spectrum, 10(4):e02206-22, DOI:10.1128/spectrum.02206-22.

Gatti M, Cojutti PG, Pea F (2024) Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: a systematic review and meta-analysis. Journal of Global Antimicrobial Resistance, 39:27-36, DOI:10.1016/j.jgar.2024.08.002.

Capsoni N, Bettina M, Bellone B, Bossi IE, Cantù L, Rossmann M, Scarnera M, Serrai I, Vergani S, Privitera D, et al (2026) Empirical piperacillin/tazobactam vs carbapenems to treat bloodstream infections due to ESBL enterobacterales: a propensity score-matched observational study conducted in an emergency department in Northern Italy. Infectious Diseases, 58(5):495-506, DOI:10.1080/23744235.2025.2600010.

Sartelli M, Palmieri M, Labricciosa FM (2025) Antibiotics for Intra-Abdominal Infections: When, Which, How and How Long? Antibiotics, 14(11):1127, DOI:10.3390/antibiotics14111127.

Gomi H, Solomkin JS, Schlossberg D, Okamoto K, Takada T, Strasberg SM, et al (2018) Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. Journal of Hepato-Biliary-Pancreatic Sciences, 25(1):3-16, DOI:10.1002/jhbp.518.

Alshehail BM, Alwezzeh MJ, Al Jamea Z, et al (2025) Effectiveness of Carbapenem-Sparing Antibiotics Versus Carbapenems for Treating Non-Bacteremic Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Infections. Infection and Drug Resistance, 18:6113-6128, DOI:10.2147/idr.s534094.

Gardner A, Nieberg P, Sakoulas G, Wong-Beringer A (2025) Carbapenem de-escalation as an antimicrobial stewardship strategy: a narrative review. JAC-Antimicrobial Resistance, 7(2):dlaf022, DOI:10.1093/jacamr/dlaf022.

Kourbeti I, Kamiliou A, Samarkos M (2024) Antibiotic Stewardship in Surgical Departments. Antibiotics, 13(4):329, DOI:10.3390/antibiotics13040329.

Itani R, Khojah HMJ, Raychouni H, Kibrit R, Shuhaiber P, Dib C, Hassan M, Mukattash TL, El-Lakany A (2025) Management practices and mortality predictors among Klebsiella pneumoniae infections across Lebanese hospitals: a multicenter retrospective study. BMC Infectious Diseases, 25(1):620, DOI:10.1186/s12879-025-11010-5.

Downloads

Published

2024-12-15